Comparison of the 2021 European Group on Graves' orbitopathy (EUGOGO) guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy

High concordance on classification, assessment, prevention, and treatment of mild, moderate-to-severe inactive and sight-threatening GO

Moderate-to-severe active GO: EUGOGO indicates intravenous glucocorticoids (IVGC) (with/without mycophenolate) first-line; ATA/ETA indicates teprotumumab first-line for virtually all phenotypes, particularly when exophthalmos predominates

ATA/ETA: IVGC preferred when goal is GO inactivation and resolution of inflammation, and among preferred treatments (with orbital radiotherapy) for inactivation and correction of eye dysmotility

Future revisions to consider: biologicals (teprotumumab, tocilizumab) for dysthyroid optic neuropathy; teprotumumab for longstanding inactive GO; reconsidering cautious RAI use in moderate-to-severe active GO treated with IVGC (with/without orbital radiotherapy); statins as adjunct therapy